Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes
Author(s)
Wei, AH; Seymour, JF;
Journal Title
British Journal of Haematology
Publication Type
epub ahead of print
Abstract
Hypomethylating agents remain the current standard of care for patients with higher-risk myelodysplastic syndromes. Ades et al. report outcomes from a randomised 'pick-a-winner' study design that examined the addition of either lenalidomide, valproic acid or idarubicin in combination with azacitidine, compared to azacitidine alone. Commentary on: Ades et al. A randomised phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS: GFM's 'pick a winner' trial, with the impact of somatic mutations. Br J Haematol 2022 (Online ahead of print). doi: 10.1111/bjh.18193.
WEHI Research Division(s)
Blood Cells And Blood Cancer
PubMed ID
35544384
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2022-05-13 08:15:14
Last Modified: 2022-05-13 08:15:34
An error has occurred. This application may no longer respond until reloaded. Reload 🗙